This company listing is no longer active
Resumen de acción OKYO
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de OKYO Pharma Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.91 |
| 52 Week High | UK£3.90 |
| 52 Week Low | UK£0.88 |
| Beta | -0.062 |
| 1 Month Change | -9.68% |
| 3 Month Change | -65.69% |
| 1 Year Change | -63.64% |
| 3 Year Change | -45.10% |
| 5 Year Change | n/a |
| Change since IPO | -98.13% |
Noticias y actualizaciones recientes
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02Rentabilidad de los accionistas
| OKYO | GB Biotechs | Mercado GB | |
|---|---|---|---|
| 7D | -31.7% | 3.9% | 0.7% |
| 1Y | -63.6% | -26.7% | 3.0% |
Rentabilidad vs. Industria: OKYO underperformed the UK Biotechs industry which returned -16.5% over the past year.
Rentabilidad vs. Mercado: OKYO underperformed the UK Market which returned -2.2% over the past year.
Volatilidad de los precios
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Precio estable de las acciones: OKYO's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: OKYO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 7 | Gary Jacob | www.okyopharma.com |
Resumen de fundamentos de OKYO Pharma Limited
| Estadísticas fundamentales de OKYO | |
|---|---|
| Capitalización bursátil | UK£23.22m |
| Beneficios(TTM) | -UK£6.70m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-3.5x
Ratio precio-beneficio (PE)¿Está OKYO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de OKYO | |
|---|---|
| Ingresos | UK£0 |
| Coste de los ingresos | UK£4.39m |
| Beneficio bruto | -UK£4.39m |
| Otros gastos | UK£2.31m |
| Beneficios | -UK£6.70m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.26 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado OKYO a largo plazo?
Ver rendimiento histórico y comparativa